Your browser doesn't support javascript.
loading
Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.
O'Rourke, Sara M; Schweighardt, Becky; Phung, Pham; Mesa, Kathryn A; Vollrath, Aaron L; Tatsuno, Gwen P; To, Briana; Sinangil, Faruk; Limoli, Kay; Wrin, Terri; Berman, Phillip W.
Afiliación
  • O'Rourke SM; Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, California, USA.
J Virol ; 86(22): 12105-14, 2012 Nov.
Article en En | MEDLINE | ID: mdl-22933284
ABSTRACT
The swarm of quasispecies that evolves in each HIV-1-infected individual represents a source of closely related Env protein variants that can be used to explore various aspects of HIV-1 biology. In this study, we made use of these variants to identify mutations that confer sensitivity and resistance to the broadly neutralizing antibodies found in the sera of selected HIV-1-infected individuals. For these studies, libraries of Env proteins were cloned from infected subjects and screened for infectivity and neutralization sensitivity. The nucleotide sequences of the Env proteins were then compared for pairs of neutralization-sensitive and -resistant viruses. In vitro mutagenesis was used to identify the specific amino acids responsible for the neutralization phenotype. All of the mutations altering neutralization sensitivity/resistance appeared to induce conformational changes that simultaneously enhanced the exposure of two or more epitopes located in different regions of gp160. These mutations appeared to occur at unique positions required to maintain the quaternary structure of the gp160 trimer, as well as conformational masking of epitopes targeted by neutralizing antibodies. Our results show that sequences in gp41, the CD4 binding site, and the V2 domain all have the ability to act as global regulators of neutralization sensitivity. Our results also suggest that neutralization assays designed to support the development of vaccines and therapeutics targeting the HIV-1 Env protein should consider virus variation within individuals as well as virus variation between individuals.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Proteína gp41 de Envoltorio del VIH / VIH-1 / Anticuerpos Neutralizantes Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Virol Año: 2012 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Proteína gp41 de Envoltorio del VIH / VIH-1 / Anticuerpos Neutralizantes Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Virol Año: 2012 Tipo del documento: Article País de afiliación: Estados Unidos